Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Michele Aieta"'
Autor:
Laura Orlando, Evaristo Maiello, Michele Orditura, Anna Diana, Giuliano Antoniol, Maria Grazia Morritti, Michele Aieta, Mariangela Ciccarese, Salvatore Pisconti, Roberto Bordonaro, Antonio Russo, Antonio Febbraro, Paola Schiavone, Annamaria Quaranta, Chiara Caliolo, Dario Loparco, Margherita Cinefra, Giuseppe Colucci, Saverio Cinieri
Publikováno v:
Breast, Vol 75, Iss , Pp 103725- (2024)
Background: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II study, comparing metronomic regimen with standard schedule
Externí odkaz:
https://doaj.org/article/f8bb73659cf247ab88a3fb4350dd4d67
Autor:
Simona Laurino, Mariarita Brancaccio, Tiziana Angrisano, Giovanni Calice, Sabino Russi, Pellegrino Mazzone, Giuseppina Di Paola, Michele Aieta, Vitina Grieco, Gabriella Bianchino, Geppino Falco, Tiziana Notarangelo
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 694 (2023)
Gastric cancer, the second most common cause of death worldwide, is characterized by poor prognosis and low responsiveness to chemotherapy. Indeed, multidrug resistance, based mainly on cellular and molecular factors, remains one of the most limiting
Externí odkaz:
https://doaj.org/article/619079da2c6f4cfcb3bcf126f79f6be4
Autor:
Laura Orlando, Vito Lorusso, Francesco Giotta, Massimo Di Maio, Paola Schiavone, Palma Fedele, Annamaria Quaranta, Chiara Caliolo, Mariangela Ciccarese, Margherita Cinefra, Sante Romito, Salvatore Pisconti, Salvatore del Prete, Michele Aieta, Daniele Rizzi, Evaristo Maiello, Giuseppe Colucci, Saverio Cinieri
Publikováno v:
Breast, Vol 53, Iss , Pp 18-22 (2020)
Background. The combination of chemotherapy plus anti HER-2 agents is the mainstay of HER-2 positive advanced breast cancer (ABC) therapy. We conducted a phase II trial testing activity and safety of trastuzumab and metronomic capecitabine/cyclophosp
Externí odkaz:
https://doaj.org/article/0d026b526bd2497c98a839bb76c7312c
Autor:
Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Francesco Giotta, Michele Aieta, Vittorio Gebbia, Antonino Musolino, Ornella Garrone, Michela Donadio, Anita Rimanti, Alessandra Beano, Claudio Zamagni, Hector Soto Parra, Federico Piacentini, Saverio Danese, Antonella Ferro, Katia Cagossi, Samanta Sarti, Anna Rita Gambaro, Sante Romito, Viviana Bazan, Laura Amaducci, Gabriella Moretti, Maria Pia Foschini, Sara Balduzzi, Roberto Vicini, Roberto D’Amico, Gaia Griguolo, Valentina Guarneri, Pier Franco Conte
Publikováno v:
BMC Medicine, Vol 17, Iss 1, Pp 1-9 (2019)
Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast can
Externí odkaz:
https://doaj.org/article/ebb6f0258ac5423e94ff695deaf0b039
Publikováno v:
Life, Vol 12, Iss 12, p 2104 (2022)
Lung cancer, of which non-small-cell lung cancer (NSCLC) represents about 80% of all cases, is the second most common cancer diagnosed in the general population and one of the major causes of cancer-related deaths worldwide. Overall, the outcomes of
Externí odkaz:
https://doaj.org/article/eedb36a624984823b0276f624cf93892
Autor:
Anna Passarelli, Giovanna Galdo, Teresa Pellegrino, Giandomenico Roviello, Michele Aieta, Raffaele Conca
Publikováno v:
Dermatology Reports (2021)
Kaposi’s sarcoma (KS) is a rare inflammation-based vascular cancer involving the skin. The viral aetiology of KS is the human herpesvirus 8 (HHV-8). KS may be frequently diagnosed in immunosuppressed kidney-transplanted patients, while is less comm
Externí odkaz:
https://doaj.org/article/e56286b2c1344a08bb346701d7d867c9
Autor:
Gaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, Carla Cavaliere, Sarah Scagliarini, Maria Giuseppa Vitale, Chiara Ciccarese, Giuseppe Di Lorenzo, Erica Palesandro, Vincenza Conteduca, Umberto Basso, Emanuele Naglieri, Azzurra Farnesi, Michele Aieta, Nicolò Borsellino, Leonardo La Torre, Gelsomina Iovane, Lucia Bonomi, Donatello Gasparro, Enrico Ricevuto, Michele De Tursi, Rocco De Vivo, Giovanni Lo Re, Francesco Grillone, Paolo Marchetti, Ferdinando De Vita, Claudio Scavelli, Claudio Sini, Salvatore Pisconti, Anna Crispo, Vittorio Gebbia, Antonio Maestri, Luca Galli, Ugo De Giorgi, Roberto Iacovelli, Carlo Buonerba, Giacomo Cartenì, Carmine D’Aniello
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-11 (2019)
Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluate
Externí odkaz:
https://doaj.org/article/ce45764abe174be68515afe7c66b3135
Autor:
Dario Trapani, Margaret Ottaviano, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Michele Aieta, Pasquale Assalone, Laura Attademo, Francesco Bloise, Davide Bosso, Valentina Borzillo, Giuseppe Buono, Giuseppe Calderoni, Francesca Caputo, Diletta Cavallero, Alessia Cavo, Raffaele Conca, Vincenza Conteduca, Stefano De Falco, Marco De Felice, Michelino De Laurentiis, Pietro De Placido, Irene De Santo, Alfonso De Stefano, Rossella Di Franco, Vincenzo Di Lauro, Antonietta Fabbrocini, Piera Federico, Pasqualina Giordano, Mario Giuliano, Antonella Lucia Marretta, Alessia Mennitto, Sara Merler, Valeria Merz, Carlo Messina, Monica Milano, Alessandro Marco Minisini, Brigitta Mucci, Lucia Nappi, Fabiana Napolitano, Immacolata Paciolla, Martina Pagliuca, Sara Parola, Angelica Petrillo, Francovito Piantedosi, Fernanda Picozzi, Erica Pietroluongo, Veronica Prati, Vittorio Riccio, Mario Rosanova, Alice Rossi, Anna Russo, Giuseppe Santabarbara, Antonia Silvestri, Massimiliano Spada, Paolo Tarantino, Paola Taveggia, Federica Tomei, Tortora Vincenzo, Claudia Trojanello, Sabrina Vari, Jole Ventriglia, Fabiana Vitiello, Caterina Vivaldi, Claudia von Arx, Francesca Zacchi, Ilaria Zampiva, Andrea Zivi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We d
Externí odkaz:
https://doaj.org/article/64743faa9b7a4b10b9520d6339d9ebce
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Despite the relevant antitumor efficacy of immunotherapy in advanced non-small cell lung cancer (NSCLC), the results in patients whose cancer harbors activating epidermal growth factor receptor (EGFR) mutations are disappointing. The biological mecha
Externí odkaz:
https://doaj.org/article/75bc51ebb5314e41b84cd5bbdbf4f44c
Autor:
Michele Guida, Stefania Tommasi, Sabino Strippoli, Maria Iole Natalicchio, Simona De Summa, Rosamaria Pinto, Antonio Cramarossa, Anna Albano, Salvatore Pisconti, Michele Aieta, Ruggiero Ridolfi, Amalia Azzariti, Gabriella Guida, Vito Lorusso, Giusepe Colucci
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background It is frequently asked whether chemotherapy can still play a role in metastatic melanoma considering the effectiveness of the available drugs today, including antiCTLA4/antiPD1 immunotherapy and antiBRAF/antiMEK inhibitors. Howeve
Externí odkaz:
https://doaj.org/article/ef5c5b859bbd4e1395b3a0fa51ed24ba